This led to the identification of a mutational signature present in more than 30% of CRC cases as sufficient for predicting sensitivity to MEK-inhibitors independent of the RAS and BRAF mutational status of the tumor. The gene discussed is MAP2K7; the disease is colorectal carcinoma.